| Market Capitalization (Millions $) |
288 |
| Shares
Outstanding (Millions) |
60 |
| Employees |
201 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc. is a biotechnology company that aims to develop next-generation therapies for immune-related disorders, including ocular and rare diseases. The company strives to leverage its proprietary technology platform to design and develop novel drug candidates that can effectively target the underlying causes of these conditions.
Founded in 2004, Aldeyra Therapeutics has made significant progress in advancing its drug pipeline using its innovative technologies. The company's research is primarily centered on developing novel approaches to modulate the immune system to treat diseases, such as dry eye syndrome, allergic conjunctivitis, and Sj'gren's syndrome, a rare autoimmune disorder.
Aldeyra Therapeutics focuses on two key areas:
Developing a pipeline of ophthalmic drug candidates: Aldeyra Therapeutics is developing a range of innovative eye drop solutions to treat various eye conditions, including dry eye syndrome and allergic conjunctivitis. The company has designed an innovative approach to target inflammation in the eye, which is the underlying cause of many eye-related diseases.
Developing a pipeline of drug candidates for rare and immune-mediated diseases: Aldeyra Therapeutics is developing a range of biologic and small molecule therapies to target rare and immune-mediated diseases. The company's lead candidate, ADX-102, is a small-molecule inhibitor that targets inflammation and can potentially treat Sj'gren's syndrome.
The company's drug development pipeline comprises several compounds in various stages of development, including pre-clinical and clinical stages. Aldeyra Therapeutics has a team of experienced drug development professionals, including scientists, medical professionals, and clinicians.
Aldeyra Therapeutics has also secured several partnerships with leading pharmaceutical companies to advance its drug development programs. The company has partnered with Janssen Pharmaceutica and LG Life Sciences to develop its drug candidates for ocular diseases.
In conclusion, Aldeyra Therapeutics is a promising biotech company that is using innovative technologies to develop novel therapies for immune-related disorders. With a strong pipeline of drug candidates in development and strategic partnerships with leading pharmaceutical companies, the company is poised for significant growth and success in the biotech industry.
Company Address: 131 Hartwell Avenue Lexington 2421 MA
Company Phone Number: 761-4904 Stock Exchange / Ticker: NASDAQ ALDX
|
0.000%
11.22%